ImmuneRegen NewsTuesday May 6, 6:30 am ET ImmuneRegen® Appoints Renowned Hematologist Ivan N. Rich, Ph.D. to Advisory BoardCompany gains further expertise to support corporate growth and commercialization of adult stem cell compound SCOTTSDALE, Ariz.--(BUSINESS WIRE)--ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBO), today announced it has appointed Ivan N. Rich, Ph.D., to its advisory board. Dr. Rich’s experience as the founder, chairman and C.E.O. of HemoGenix® Inc., a research laboratory specializing in stem cell applications that serves the biotechnology and pharmaceutical industries, is expected to further enhance ImmuneRegen’s growth as it focuses on research and product development of its drug candidate, the adult stem cell-active compound, Homspera®. “Dr. Rich’s experience as a renowned hematologist in marketing biochemistry products as well as his extensive knowledge of stem cell research further strengthens our company as we continue to develop product applications from Homspera’s increasingly diverse potential,” said Michael K. Wilhelm, ImmuneRegen’s President and CEO. “We are honored to have Dr. Rich join our team and look forward to his counsel in helping us define and collect the appropriate data to support industry partnerships that should maximize the opportunities to commercialize Homspera’s apparent broad spectrum of activity." Regarding its adult stem cell activity, Homspera has shown GM-CSF-like activity in elevating circulating white blood cells and the potential to treat neutropenia. Dr. Rich has presented his research at numerous international conferences and has been published in peer-reviewed journals as well as serving as a grant reviewer for agencies around the world. He is also an adjoint professor of biology at the University of Colorado at Colorado Springs. Prior to moving to the United States from Germany in 1996, Dr. Rich founded Specialized Culture Technologies, which focused on providing unique cell culture equipment and accessories to research scientists. He has organized and edited conference proceedings for a NATO Advanced Research Workshop and helped organize and edit the proceedings of a New York Academy of Science Workshop on erythropoietin. His industry-related memberships include the American Society of Hematology, International Society of Experimental Hematology, British Society of Hematology, International Society of Cellular Therapy, Society of Toxicology and Society of Biomolecular Screening. He is also a reviewer for many scientific journals. Dr. Rich holds a Ph.D. from the University of Ulm in Ulm, Germany. In addition to having completed a second thesis on experimental hematology, he performed postdoctoral research at the University of Chicago with Dr. Eugene Goldwasser who was responsible for obtaining the first partial amino acid sequence of purified erythropoietin (EPO), which led to the production of the first human recombinant EPO used around the world to alleviate the symptoms of chronic anemia.
About ImmuneRegen BioSciences, Inc.ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBO), is a development-stage biotechnology company focused on the research, development and licensing of HomsperaŽ, an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, Lovelace Respiratory Research Institute, UC Berkeley, HemoGenix and Virion Systems, Inc. For more information, please visit the company's website at www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended March 31, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: ### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|
